Nanoscale, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
This review highlights recent stimulus-responsive antimicrobial nanotherapeutics for ocular infections, focusing on their design, progress, and advantages/limitations.
Язык: Английский
Proceedings of the National Academy of Sciences, Год журнала: 2025, Номер 122(11)
Опубликована: Март 11, 2025
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating exploration multimodal immunotherapy combinations. Traditional approaches combining conventional checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion systemic toxicity. Hence, novel needed to address these challenges. Herein, we demonstrate that mRNA polymeric nanoparticles encoding anti-PD-1 antibodies situ at tumor site enhance therapeutic neoantigen-based vaccine for PDAC. This mRNA-based, antibody production strategy also protects tumor-infiltrating cells from PD-1 inhibition, potentially reducing toxicities induced inhibition. Our study may provide an innovative dual nanoparticle effective immunotherapy, as well cancer combination therapy other clinically approved drugs (e.g., β-elemene).
Язык: Английский
Процитировано
1
Expert Opinion on Drug Delivery, Год журнала: 2024, Номер 21(10), С. 1415 - 1439
Опубликована: Сен. 14, 2024
Nucleic acid-based therapies are promising advancements in medicine. They offer unparalleled efficacy treating previously untreatable diseases through precise gene manipulation techniques. However, the challenge of achieving targeted delivery to specific cells remains a significant obstacle.
Язык: Английский
Процитировано
3
Journal of drug targeting, Год журнала: 2025, Номер unknown, С. 1 - 20
Опубликована: Янв. 3, 2025
Vision loss and blindness are significant issues in both developed developing countries. There a wide variety of aetiologies that can cause vision loss, which outlined this review. Although treatment has significantly improved over time for some conditions, nearly half all people with impairment left untreated. Gene delivery is an emerging field may assist the these difficult to manage forms loss. Here we review how component nanotechnology-based, non-viral gene systems being applied help resolve impairment. This focuses on use lipid polymer nanoparticles, quantum dots as vectors eye. Finally, also highlight technologies be useful discipline.
Язык: Английский
Процитировано
0
Cell Communication and Signaling, Год журнала: 2025, Номер 23(1)
Опубликована: Янв. 10, 2025
Ischemic retinopathies are the major causes of blindness, yet effective early-stage treatments remain limited due to an incomplete understanding underlying molecular mechanisms. Significant changes in gene expression often precede structural and functional alterations. Transfer RNA (tRNA)-derived small RNAs (tsRNAs) emerging as novel regulators, involved various biological processes human diseases. In this study, tsRNA-Gln-i-0095 was identified a regulator, which significantly upregulated retinal ischemia/reperfusion (I/R) injury. Reducing levels suppressed reactive gliosis, lowered inflammatory cytokine levels, protected ganglion cells from I/R These effects led reduced damage, inhibited glial activation inflammation, enhanced neuronal function. Mechanistically, downregulated NFIA TGFBR2 through miRNA-like mechanism. Collectively, study highlights potential targeting therapeutic approach reduce injury preserve visual
Язык: Английский
Процитировано
0
Frontiers in Pharmacology, Год журнала: 2025, Номер 16
Опубликована: Янв. 23, 2025
Blue light induced eye damage (BLED) belongs to modern diseases. It is an ophthalmic disease caused by prolonged exposure electronic devices or screens containing a large amount of high-energy short waves (blue light). Specific symptoms include dryness and discomfort in the eyes, blurred vision, headache, insomnia, severe cases, it may also cause various diseases such as cataracts glaucoma. At present, development health products drugs for blue injury faces many difficulties. Therefore, further exploration research are needed on pathogenesis, pathophysiology, pharmacological mechanisms injury. Natural medicine ingredients preparations have unique advantages targeting fatigue due their multi-component synergistic effects, overall regulation, mild safe characteristics. Starting from disease-related pathophysiological characteristics injury, this article elucidates treating same time, reviews vitro cultured cell animal model conditions order provide reference subsequent modeling experiments. And explore future directions new ideas methods prevention treatment BLED.
Язык: Английский
Процитировано
0
Advanced Functional Materials, Год журнала: 2025, Номер unknown
Опубликована: Март 17, 2025
Abstract The corneal lenticules extracted from small incision lenticule extraction (SMILE) can be used as an optional transplantation material. However, it cannot for deep anterior lamellar keratoplasty due to its thickness limitations. In this study, oxidized chondroitin sulfate (O─CS) containing ─SO 3 − groups twisted with generation 4.0 polyamidoamine dendrimers (G4 PAMAM) which contain −NH 2 + via electrostatic entanglement form a cohesive module, is applicable in suture‐free of cornea, providing the possibility repairing defects. intermolecular enhanced self‐adhesion module (33.80 ± 2.12 kPa) high light transmittance (more than 70%) and excellent biocompatibility, benefits stable adhesion long term. Additionally, G4 PAMAM control long‐term puerarin drug release then inhibit postoperative inflammatory response. bioself‐adhesion between macromolecules realize tissues, provides promising strategy living tissue wound repair.
Язык: Английский
Процитировано
0
Nanoscale, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
This review highlights recent stimulus-responsive antimicrobial nanotherapeutics for ocular infections, focusing on their design, progress, and advantages/limitations.
Язык: Английский
Процитировано
0